Kidney injury molecule 1 (KIM-1): a potential biomarker of acute kidney injury and tubulointerstitial injury in patients with ANCA-glomerulonephritis.
ANCA
KIM-1
glomerulonephritis
tubulointerstitial injury
vasculitis
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
23
05
2022
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Kidney injury molecule 1 (KIM-1) is a transmembrane glycoprotein expressed by proximal tubular cells, recognized as an early, sensitive and specific urinary biomarker for kidney injury. Blood KIM-1 was recently associated with the severity of acute and chronic kidney damage but its value in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis with glomerulonephritis (ANCA-GN) has not been studied. Thus, we analyzed its expression at ANCA-GN diagnosis and its relationship with clinical presentation, kidney histopathology and early outcomes. We assessed KIM-1 levels and other pro-inflammatory molecules (C-reactive protein, interleukin-6, tumor necrosis factor α, monocyte chemoattractant protein-1 and pentraxin 3) at ANCA-GN diagnosis and after 6 months in patients included in the Maine-Anjou registry, which gathers data patients from four French Nephrology Centers diagnosed since January 2000. Blood KIM-1 levels were assessed in 54 patients. Levels were elevated at diagnosis and decreased after induction remission therapy. KIM-1 was associated with the severity of renal injury at diagnosis and the need for kidney replacement therapy. In opposition to other pro-inflammatory molecules, KIM-1 correlated with the amount of acute tubular necrosis and interstitial fibrosis/tubular atrophy (IF/TA) on kidney biopsy, but not with interstitial infiltrate or with glomerular involvement. In multivariable analysis, elevated KIM-1 predicted initial estimated glomerular filtration rate (β = -19, 95% CI -31, -7.6, KIM-1 appears as a potential biomarker for acute kidney injury and for tubulointerstitial injury in ANCA-GN. Whether KIM-1 is only a surrogate marker or is a key immune player in ANCA-GN pathogenesis remain to be determined.
Sections du résumé
Background
UNASSIGNED
Kidney injury molecule 1 (KIM-1) is a transmembrane glycoprotein expressed by proximal tubular cells, recognized as an early, sensitive and specific urinary biomarker for kidney injury. Blood KIM-1 was recently associated with the severity of acute and chronic kidney damage but its value in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis with glomerulonephritis (ANCA-GN) has not been studied. Thus, we analyzed its expression at ANCA-GN diagnosis and its relationship with clinical presentation, kidney histopathology and early outcomes.
Methods
UNASSIGNED
We assessed KIM-1 levels and other pro-inflammatory molecules (C-reactive protein, interleukin-6, tumor necrosis factor α, monocyte chemoattractant protein-1 and pentraxin 3) at ANCA-GN diagnosis and after 6 months in patients included in the Maine-Anjou registry, which gathers data patients from four French Nephrology Centers diagnosed since January 2000.
Results
UNASSIGNED
Blood KIM-1 levels were assessed in 54 patients. Levels were elevated at diagnosis and decreased after induction remission therapy. KIM-1 was associated with the severity of renal injury at diagnosis and the need for kidney replacement therapy. In opposition to other pro-inflammatory molecules, KIM-1 correlated with the amount of acute tubular necrosis and interstitial fibrosis/tubular atrophy (IF/TA) on kidney biopsy, but not with interstitial infiltrate or with glomerular involvement. In multivariable analysis, elevated KIM-1 predicted initial estimated glomerular filtration rate (β = -19, 95% CI -31, -7.6,
Conclusion
UNASSIGNED
KIM-1 appears as a potential biomarker for acute kidney injury and for tubulointerstitial injury in ANCA-GN. Whether KIM-1 is only a surrogate marker or is a key immune player in ANCA-GN pathogenesis remain to be determined.
Identifiants
pubmed: 37664565
doi: 10.1093/ckj/sfad071
pii: sfad071
pmc: PMC10468750
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1521-1533Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Déclaration de conflit d'intérêts
S.W. and G.B.P. are members of the CKJ editorial board. The other authors declare that they have no conflicts of interest in relation to this article.
Références
J Rheumatol. 2013 May;40(5):674-83
pubmed: 23547217
J Clin Invest. 2015 Apr;125(4):1620-36
pubmed: 25751064
BMJ. 2020 Mar 18;368:m421
pubmed: 32188597
Kidney Int. 2018 Dec;94(6):1177-1188
pubmed: 30385041
J Am Soc Nephrol. 2014 Oct;25(10):2177-86
pubmed: 24904085
J Clin Invest. 2008 May;118(5):1657-68
pubmed: 18414680
Nat Rev Dis Primers. 2020 Aug 27;6(1):71
pubmed: 32855422
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1103-1111
pubmed: 32723805
J Immunol. 2010 Nov 1;185(9):5225-35
pubmed: 20889552
Arch Med Res. 2017 Jul;48(5):449-458
pubmed: 29122357
Nephrol Dial Transplant. 2020 Feb 1;35(2):265-273
pubmed: 30629206
Autoimmun Rev. 2013 Feb;12(4):477-82
pubmed: 22921791
J Clin Invest. 2008 Feb;118(2):742-51
pubmed: 18172549
Nephrol Dial Transplant. 2022 May 25;37(6):1078-1087
pubmed: 33856482
Exp Ther Med. 2014 May;7(5):1130-1134
pubmed: 24940398
QJM. 1994 Nov;87(11):671-8
pubmed: 7820541
Biochem Biophys Res Commun. 2011 Mar 11;406(2):223-8
pubmed: 21303660
Front Immunol. 2022 Mar 22;13:834878
pubmed: 35392077
Am J Surg Pathol. 2018 May;42(5):625-635
pubmed: 29537990
Microvasc Res. 2009 Jan;77(1):4-7
pubmed: 18938184
Presse Med. 2020 Oct;49(3):104031
pubmed: 32645418
J Am Soc Nephrol. 2010 Oct;21(10):1628-36
pubmed: 20616173
Nat Biotechnol. 2010 May;28(5):478-85
pubmed: 20458318
Medicine (Baltimore). 2016 Nov;95(44):e5264
pubmed: 27858892
J Diabetes Investig. 2020 Mar;11(2):435-440
pubmed: 31483944
J Immunol. 2007 Apr 1;178(7):4342-50
pubmed: 17371991
Kidney Int. 2002 Nov;62(5):1539-49
pubmed: 12371954
Kidney Int. 2017 Jan;91(1):196-203
pubmed: 28029431
Cell Metab. 2021 May 4;33(5):1042-1061.e7
pubmed: 33951465
J Biol Chem. 1998 Feb 13;273(7):4135-42
pubmed: 9461608
Kidney Int. 2002 Jul;62(1):237-44
pubmed: 12081583
Kidney Blood Press Res. 2018;43(4):1255-1262
pubmed: 30078006
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Kidney Int. 2011 May;79(10):1113-8
pubmed: 21270761
Int J Rheum Dis. 2020 Aug;23(9):1184-1193
pubmed: 32627422
Am J Physiol. 1979 Oct;237(4):F319-25
pubmed: 495725
Ter Arkh. 2017;89(6):48-55
pubmed: 28745689
Kidney Int. 2012 May;81(9):844-55
pubmed: 22205357
J Clin Invest. 2013 Sep;123(9):4023-35
pubmed: 23979159
Toxicol Sci. 2013 Jan;131(1):13-25
pubmed: 23019274
Kidney Int. 2021 Oct;100(4):753-779
pubmed: 34556300
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Am J Kidney Dis. 2022 Feb;79(2):231-243.e1
pubmed: 34175376
Nephrol Dial Transplant. 2023 May 4;38(5):1192-1203
pubmed: 36043422
Am J Transplant. 2020 Sep;20(9):2305-2317
pubmed: 32428337
J Immunol. 2015 Feb 15;194(4):1602-8
pubmed: 25582854
Am J Physiol Renal Physiol. 2014 May 15;306(10):F1210-21
pubmed: 24623145